18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine
| Autor: | Thomas C. Lauenstein, Lino M Sawicki, Ken Herrmann, Karsten Beiderwellen, Julian Kirchner, Lale Umutlu, J Grüneisen, Michael Forsting, Philipp Heusch, Cornelius Deuschl |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Male
Medizin lcsh:Medicine Contrast Media Pathology and Laboratory Medicine 030218 nuclear medicine & medical imaging Diagnostic Radiology Cholangiocarcinoma 0302 clinical medicine Positron Emission Tomography Computed Tomography Medicine and Health Sciences Contrast (vision) lcsh:Science Melanoma media_common Multidisciplinary medicine.diagnostic_test Radiology and Imaging Liver Diseases Liver Neoplasms Middle Aged Magnetic Resonance Imaging Adenomas Liver Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma Female Radiology medicine.symptom Colorectal Neoplasms Research Article Hepatic Resection Adult medicine.medical_specialty Carcinoma Hepatocellular Imaging Techniques media_common.quotation_subject Breast Neoplasms Surgical and Invasive Medical Procedures Gastroenterology and Hepatology Research and Analysis Methods Sensitivity and Specificity Carcinomas Lesion 03 medical and health sciences Digestive System Procedures Text mining Meglumine Signs and Symptoms Fluorodeoxyglucose F18 Diagnostic Medicine Gastrointestinal Tumors medicine Carcinoma Organometallic Compounds Cancer Detection and Diagnosis Humans In patient GADOBENATE DIMEGLUMINE Aged Surgical Resection business.industry lcsh:R Cancers and Neoplasms Magnetic resonance imaging Hepatocellular Carcinoma medicine.disease Lesions Gastrointestinal Imaging lcsh:Q Radiopharmaceuticals business Liver and Spleen Scan |
| Zdroj: | PLoS ONE PLoS ONE, Vol 12, Iss 7, p e0180349 (2017) |
| Popis: | Objectives To evaluate the added value of the application of the liver-specific contrast phase of Gadobenate dimeglumine (Gd-BOPTA) for detection and characterization of liver lesions in 18F-FDG PET/MRI. Methods 41 patients with histologically confirmed solid tumors and known / suspected liver metastases or not classifiable lesions in 18F-FDG PET/CT were included in this study. All patients underwent a subsequent Gd-BOPTA enhanced 18F-FDG PET/MRI examination. MRI without liver-specific contrast phase (MRI1), MRI with liver-specific contrast phase (MRI2), 18F-FDG PET/MRI without liver-specific contrast phase (PET/MRI1) and with liver-specific contrast phase (PET/MRI2) were separately evaluated for suspect lesions regarding lesion dignity, characterization, conspicuity and confidence. Results PET/MRI datasets enabled correct identification of 18/18 patients with malignant lesions; MRI datasets correctly identified 17/18 patients. On a lesion-based analysis PET/MRI2 provided highest accuracy for differentiation of lesions into malignant and benign lesions of 98% and 100%. Respective values were 95% and 100% for PET/MRI1, 93% and 96% for MRI2 and 91% and 93% for MRI1. Statistically significant higher diagnostic confidence was found for PET/MRI2 and MRI2 datasets compared to PET/MRI1 and MRI1, respectively (p < 0.001). Conclusion The application of the liver-specific contrast phase in 18F-FDG PET/MRI further increases the diagnostic accuracy and diagnostic confidence for correct assessment of benign and malignant liver lesions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|